Investigation of Metabolomics Differences Between Metabolic Syndrome and Healthy Individuals in Taiwan
Investigation of Metabolite Differences Between Taiwanese Metabolic Syndrome and Healthy Group Through Metabolomics
1 other identifier
observational
1,200
0 countries
N/A
Brief Summary
The prevalence of metabolic syndrome in Taiwan has been increasing yearly. In this project, the database of blood test results from healthy and metabolic syndromes individuals will be analyzed to identify the small molecules related to the severity of metabolic syndrome. These identified small molecules could be used as biomarkers to predict the development of metabolic syndromes in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2024
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 9, 2024
CompletedFirst Posted
Study publicly available on registry
April 12, 2024
CompletedStudy Start
First participant enrolled
April 14, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 31, 2029
April 12, 2024
April 1, 2024
5.6 years
April 9, 2024
April 9, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Concentration changes of small molecules in blood.
Concentrations of small molecules in healthy individuals and metabolic syndrom patients will be analyzed to identify specific biomarkers for metabolic syndrome.
Up to six years
Study Arms (2)
Healthy individuals
Metabolic syndrome patients
Eligibility Criteria
Healthy individuals and patients with metabolic syndrom.
You may qualify if:
- Capable adults weigh ≥ 50 kg
You may not qualify if:
- Not Taiwanese
- Having received oral antibiotics, immunosuppressants, and chemotherapy drugs in the past month
- Incapacity
- Limited disposing capacity
- Mental disorders or intellectual disabilities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 9, 2024
First Posted
April 12, 2024
Study Start
April 14, 2024
Primary Completion (Estimated)
October 31, 2029
Study Completion (Estimated)
October 31, 2029
Last Updated
April 12, 2024
Record last verified: 2024-04